Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia
The objective: to evaluate the effectiveness of inhaled surfactant therapy in the integrated treatment of severe COVID-19 pneumonia in a multicenter prospective clinical trial of surfactant-BL.Subjects and methods. 122 patients with severe COVID-19-associated pneumonia treated in two treatment cente...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2020-10-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1456 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850223898561347584 |
|---|---|
| author | A. E. Bautin S. N. Avdeev A. A. Seyliev M. V. Shvechkova Z. M. Merzhoeva N. V. Trushenko A. P. Semenov K. B. Lapshin O. A. Rozenberg |
| author_facet | A. E. Bautin S. N. Avdeev A. A. Seyliev M. V. Shvechkova Z. M. Merzhoeva N. V. Trushenko A. P. Semenov K. B. Lapshin O. A. Rozenberg |
| author_sort | A. E. Bautin |
| collection | DOAJ |
| description | The objective: to evaluate the effectiveness of inhaled surfactant therapy in the integrated treatment of severe COVID-19 pneumonia in a multicenter prospective clinical trial of surfactant-BL.Subjects and methods. 122 patients with severe COVID-19-associated pneumonia treated in two treatment centers were enrolled in the study. All of them received antiviral, anticoagulant and anti-inflammatory therapy. 56 patients also received inhalation therapy with surfactant-BL (OOO Biosurf, St. Petersburg, Russia) at a dose of 1 mg/kg 2-3 times a day. The remaining 66 patients received no surfactant-BL inhalation. When included into the study, all patients were divided into two groups based on severity of the condition at the time of inclusion: 62 people (Group I) needed oxygen inhalation through a face mask with the flow of 6-8 L/min for hypoxemia correction (27 received surfactant therapy and 35 did not); other 60 patients (Group II) required non-invasive respiratory support (constant positive airway pressure, non-invasive mechanical ventilation, high-flow oxygen therapy), of them 29 received surfactant therapy, while 31 patients did not.Results. In Group I, switching to invasive mechanical ventilation was required for 3/27 (11.1%) patients who received surfactant therapy, and 10/35 (28.6%) who received no surfactant therapy (p = 0.085); lethality made 3/27 (11.1%) and 9/35 (25.7%) (p = 0.131), respectively. In Group II, among those who received surfactant therapy, 5/29 (17.2%) were switched to invasive mechanical ventilation and 18/31 (58.1%) among those who did not receive it (p = 0.001); lethality made 5/29 (17.2%) and 18/31 (58.1%) (p = 0.001), respectively. In the pooled group of 122 patients with severe COVID-19-associated pneumonia, 8 (14.3%) of 56 patients who received surfactant died, and 27 (40.9%) of 66 died among those who did not receive it, (p = 0.001).Conclusion: Inhalation surfactant therapy can reduce the frequency of switching patients to mechanical ventilation and statistically significantly reduce lethality caused by severe pneumonia associated with SARS-CoV-2. |
| format | Article |
| id | doaj-art-bfa89b9d93084877b4cc48253743bea3 |
| institution | OA Journals |
| issn | 2075-1230 2542-1506 |
| language | Russian |
| publishDate | 2020-10-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Туберкулез и болезни лёгких |
| spelling | doaj-art-bfa89b9d93084877b4cc48253743bea32025-08-20T02:05:48ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062020-10-0198961210.21292/2075-1230-2020-98-9-6-121454Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumoniaA. E. Bautin0S. N. Avdeev1A. A. Seyliev2M. V. Shvechkova3Z. M. Merzhoeva4N. V. Trushenko5A. P. Semenov6K. B. Lapshin7O. A. Rozenberg8Almazov National Medical Research CenterI.M. Sechenov First Moscow State Medical University (Sechenov University)A.M. Granov Russian Research Center of Radiology and Surgical TechnologiesPerinatal CenterI.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Almazov National Medical Research CenterAlmazov National Medical Research CenterA.M. Granov Russian Research Center of Radiology and Surgical TechnologiesThe objective: to evaluate the effectiveness of inhaled surfactant therapy in the integrated treatment of severe COVID-19 pneumonia in a multicenter prospective clinical trial of surfactant-BL.Subjects and methods. 122 patients with severe COVID-19-associated pneumonia treated in two treatment centers were enrolled in the study. All of them received antiviral, anticoagulant and anti-inflammatory therapy. 56 patients also received inhalation therapy with surfactant-BL (OOO Biosurf, St. Petersburg, Russia) at a dose of 1 mg/kg 2-3 times a day. The remaining 66 patients received no surfactant-BL inhalation. When included into the study, all patients were divided into two groups based on severity of the condition at the time of inclusion: 62 people (Group I) needed oxygen inhalation through a face mask with the flow of 6-8 L/min for hypoxemia correction (27 received surfactant therapy and 35 did not); other 60 patients (Group II) required non-invasive respiratory support (constant positive airway pressure, non-invasive mechanical ventilation, high-flow oxygen therapy), of them 29 received surfactant therapy, while 31 patients did not.Results. In Group I, switching to invasive mechanical ventilation was required for 3/27 (11.1%) patients who received surfactant therapy, and 10/35 (28.6%) who received no surfactant therapy (p = 0.085); lethality made 3/27 (11.1%) and 9/35 (25.7%) (p = 0.131), respectively. In Group II, among those who received surfactant therapy, 5/29 (17.2%) were switched to invasive mechanical ventilation and 18/31 (58.1%) among those who did not receive it (p = 0.001); lethality made 5/29 (17.2%) and 18/31 (58.1%) (p = 0.001), respectively. In the pooled group of 122 patients with severe COVID-19-associated pneumonia, 8 (14.3%) of 56 patients who received surfactant died, and 27 (40.9%) of 66 died among those who did not receive it, (p = 0.001).Conclusion: Inhalation surfactant therapy can reduce the frequency of switching patients to mechanical ventilation and statistically significantly reduce lethality caused by severe pneumonia associated with SARS-CoV-2.https://www.tibl-journal.com/jour/article/view/1456covid-19influenza a/h1n1viral pneumoniaardsacute respiratory failure |
| spellingShingle | A. E. Bautin S. N. Avdeev A. A. Seyliev M. V. Shvechkova Z. M. Merzhoeva N. V. Trushenko A. P. Semenov K. B. Lapshin O. A. Rozenberg Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia Туберкулез и болезни лёгких covid-19 influenza a/h1n1 viral pneumonia ards acute respiratory failure |
| title | Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia |
| title_full | Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia |
| title_fullStr | Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia |
| title_full_unstemmed | Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia |
| title_short | Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia |
| title_sort | inhalation surfactant therapy in the integrated treatment of severe covid 19 pneumonia |
| topic | covid-19 influenza a/h1n1 viral pneumonia ards acute respiratory failure |
| url | https://www.tibl-journal.com/jour/article/view/1456 |
| work_keys_str_mv | AT aebautin inhalationsurfactanttherapyintheintegratedtreatmentofseverecovid19pneumonia AT snavdeev inhalationsurfactanttherapyintheintegratedtreatmentofseverecovid19pneumonia AT aaseyliev inhalationsurfactanttherapyintheintegratedtreatmentofseverecovid19pneumonia AT mvshvechkova inhalationsurfactanttherapyintheintegratedtreatmentofseverecovid19pneumonia AT zmmerzhoeva inhalationsurfactanttherapyintheintegratedtreatmentofseverecovid19pneumonia AT nvtrushenko inhalationsurfactanttherapyintheintegratedtreatmentofseverecovid19pneumonia AT apsemenov inhalationsurfactanttherapyintheintegratedtreatmentofseverecovid19pneumonia AT kblapshin inhalationsurfactanttherapyintheintegratedtreatmentofseverecovid19pneumonia AT oarozenberg inhalationsurfactanttherapyintheintegratedtreatmentofseverecovid19pneumonia |